CD274 and interstitial lung disease: Previous phase III studies have reported that the incidence of interstitial lung disease (ILD) induced by anti‐PD‐1/PD‐L1 therapies was 1%‐6%.1, 2, 3, 4, 5 ILD is potentially fatal and often results in the discontinuation of therapy.3, 9 Indeed, several studies have shown that ILD was the most common irAE leading to the discontinuation of anti‐PD‐1 therapies.1, 2 On the other hand, the augmentation of antitumor effects was reported in patients with ILD, similar to other irAEs.10, 11, 12